Christopher M. Duke
Directeur Général chez Gennao Bio, Inc.
Profil
Christopher M.
Duke is currently the Chief Executive Officer at Gennao Bio, Inc. He previously worked as the Executive Director-Commercial Operations at NPS Pharmaceuticals, Inc. and as the Vice President-Global Commercial Operations at Amicus Therapeutics, Inc. From 2016 to 2018, he served as the Chief Operating Officer & Senior Vice President at Advaxis, Inc. Mr. Duke holds a graduate degree from the University of Medicine & Dentistry of New Jersey, an undergraduate degree from Rutgers State University of New Jersey, and an MBA from The Wharton School of the University of Pennsylvania.
Postes actifs de Christopher M. Duke
| Sociétés | Poste | Début |
|---|---|---|
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Directeur Général | 11/04/2023 |
Anciens postes connus de Christopher M. Duke
| Sociétés | Poste | Fin |
|---|---|---|
| AYALA PHARMACEUTICALS, INC. | Directeur des opérations | 08/06/2018 |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AMICUS THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Christopher M. Duke
| Rutgers State University of New Jersey | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Medicine & Dentistry of New Jersey | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Health Technology |
